RxDoctor Payments Data

Raphael Gabay, DO

Otolaryngology/Facial Plastic Surgery · Philadelphia, PANPI 1700863743

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Merz North America, Inc. accounts for 79.7% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $1,349 and has fallen 77.2% since, to $307 in 2025.

$3,642in general payments, 2019–2025

Across 77 payments — averaging $47.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$3K
  • Optinose US, Inc.$447
  • Mentor Worldwide LLC$143
  • Galderma Laboratories, L.p.$30
  • Acella Pharmaceuticals, LLC$21
  • Pacira Pharmaceuticals Incorporated$21
  • plus $78 from 5 others

What the payments were for

  • Food & beverage$3,642100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,642 in reported general payments places this provider in the 60th percentile of 21 otolaryngology/facial plastic surgery providers in Pennsylvania.

See all otolaryngology/facial plastic surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$121,478
Medicare patients
477
Services billed
1,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Azelastine Hcl404$6,764
Fluticasone Propionate603$6,738
Ofloxacin89$2,391
Levocetirizine Dihydrochloride269$2,352
Omeprazole130$1,029
Ciprofloxacin Hcl99$645
Methylprednisolone99$588
Hydrocortisone Valerate18$449
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav35$369
Cevimeline Hcl11$296
Clindamycin Hcl30$216
Mupirocin30$213
Montelukast Sodium12$187
Azithromycin42$180
Famotidine28$168

Paid to pharmacies, not to this prescriber.

Other otolaryngology/facial plastic surgery in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →